Komodo Health continues to invest in generative AI capabilities, seeing the potential to use AI-powered conversational language to make it easier for health research teams to parse through troves of data.
The health data company rolled out a new AI analytics assistant, MapAI, as part of its overarching platform MapLab.
MapAI and another new tool, MapExplorer, enable healthcare professionals to explore any therapeutic area simply by asking questions in plain language, according to Laurent Bride, Komodo Health's chief technology officer.
MapAI uses natural-language-processing-based generative AI to initiate an analysis of Komodo’s Healthcare Map, made up of de-identified data on more than 330 million patient interactions within the healthcare system. The no-code ChatGPT-like tool enables health research teams, even individuals with no coding experience, to rapidly evaluate drug trends, track how diseases spread and evaluate how patients are being treated, according to the company.
The offering supports faster decision-making by enabling users at any skill level or experience with healthcare data to use conversational language to get clear answers to complex analytic questions in minutes versus hours or days, Komodo Health executives said.
Komodos’s MapAI application allows users to ask healthcare-related questions using conversational language—reducing the need to pull in data experts for early-stage analyses. Research teams can ask questions like, "What is the patient breakdown of GLP-1 prescriptions by payer?" or "How many patients with a history of dementia were diagnosed with Alzheimer's in 2023?”
"For AI to truly deliver value in healthcare, a robust data foundation is essential—and that’s where Komodo’s MapAI, our latest GenAI solution, powered by our Healthcare map shines," Bride said. "Over the past decade, we've built a range of tools designed to meet users wherever they are, providing the right experiences—whether they need no-code, low-code or high-code solutions. This approach has enabled a suite of analytics that empowers life sciences, payers, providers and developers to generate and scale critical insights efficiently."
Komodo Health customers often express frustration over the time spent preparing data for analysis, Bride noted.
"They crave streamlined tools that not only simplify processes but also eliminate the need for multiple-point solutions. With these new capabilities, we’re paving the way for healthcare companies to collaborate more effectively, navigate market complexities, mitigate risks, and make data-driven decisions that drive both immediate and long-term success. And this is just the beginning of the innovations we’ll be rolling out this year," he said.
Insights gleaned from MapAI can be easily transferred into MapView, Komodo’s no-code application on the MapLab platform, featuring pre-built analytic modules for market and disease landscaping, patient and healthcare provider segmentation and brand performance monitoring.
A 2024 survey from Frost & Sullivan found that healthcare companies spend an average of seven months gathering data into a usable state.
New generative-AI-powered tools propose to be accelerants for decision-making within healthcare and life sciences organizations. They give anyone within an enterprise—regardless of their experience working with healthcare data—the ability to produce the type of net-new insights needed for critical business decisions, Komodo Health executives said.
MapAI significantly cuts down time to insights and allows users to more quickly test and iterate hypotheses before initiating deeper, costly analyses.
It marks the newest addition to the MapLab platform and is launching alongside another new, AI-enabled tool called MapExplorer. That solution is designed for companies that are new to the Healthcare Map but want to access its capabilities, equipping teams with point-and-click functionality and conversational AI features, according to the company.
Komodo Health also recently announced it was integrating Cornerstone AI's software into components of its MapEnhance offering. MapEnhance, first unveiled in 2023, features a library of specialty data sets from Komodo and its partners.
The move to integrate with Cornerstone AI follows a successful pilot program in which Cornerstone's proprietary algorithms strengthened the fidelity of Komodo's Lab Results, a product available within MapEnhance, the companies said.
Komodo claims its suite of products, including MapLab, is currently being used by over 200 life sciences and healthcare organizations, including Johnson & Johnson, Merck, Novo Nordisk, MoonLake Immunotherapeutics, Regeneron and Takeda Pharmaceuticals.
Launched in 2014 by co-founders Web Sun and Arif Nathoo, M.D., the company has raised $514 million to date, including a $220 million series E round in 2021 and a structured equity infusion of $200 million in November 2022.